login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
FOGHORN THERAPEUTICS INC (FHTX) Stock News
USA
- NASDAQ:FHTX -
US3441741077
-
Common Stock
4.45
USD
-0.05 (-1.11%)
Last: 10/9/2025, 10:45:18 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
FHTX Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Zacks Investment Research
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
a month ago - By: Zacks Investment Research
- Mentions:
ARQT
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
a month ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
a month ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
a month ago - By: Zacks Investment Research
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
2 months ago - By: Benzinga
- Mentions:
EQ
AZTR
FGEN
MYO
...
12 Health Care Stocks Moving In Monday's After-Market Session
2 months ago - By: Zacks Investment Research
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
2 months ago - By: Zacks Investment Research
- Mentions:
EXAS
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
2 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
2 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
5 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
5 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
5 months ago - By: Zacks Investment Research
- Mentions:
ATRA
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
5 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
5 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
5 months ago - By: Yahoo Finance
- Mentions:
GGG
SNA
AEO
NVO
Graco Inc. (GGG): Among Benjamin Graham Stocks for Defensive Investors
5 months ago - By: Zacks Investment Research
- Mentions:
INO
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
5 months ago - By: Zacks Investment Research
- Mentions:
STRO
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
5 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
5 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
5 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
5 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
5 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
6 months ago - By: Benzinga
- Mentions:
GIS
S
PYPL
OKLO
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday
6 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
6 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
7 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
7 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
7 months ago - By: Foghorn Therapeutics, Inc.
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
Please enable JavaScript to continue using this application.